Full text is available at the source.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists may enhance bone mineral density and reduce bone resorption.
- Basic science studies suggest GLP-1 agonists could positively affect bone health.
- Clinical studies on fracture risk and bone health show mixed results.
- The use of GLP-1 agonists in the perioperative setting may present challenges due to effects on gastric motility.
- Proper glycemic control with GLP-1 agonists is associated with potential benefits for patients with diabetes or obesity undergoing orthopedic procedures.
- Further research is required to clarify the long-term effects of GLP-1 agonists on bone health and their use in orthopedic patients.
Simplified